JP2021001178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021001178A5 JP2021001178A5 JP2020143608A JP2020143608A JP2021001178A5 JP 2021001178 A5 JP2021001178 A5 JP 2021001178A5 JP 2020143608 A JP2020143608 A JP 2020143608A JP 2020143608 A JP2020143608 A JP 2020143608A JP 2021001178 A5 JP2021001178 A5 JP 2021001178A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- isolated placental
- cells
- placental
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 description 10
- 230000003169 placental effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000004991 placental stem cell Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
Description
別の実施形態では、本明細書に記載の方法及び組成物に有用な単離胎盤細胞は、抗体結合で決定されるようなＣＤ２００＋及びＣＤ１０＋であり、抗体結合及びＲＴ－ＰＣＲの両方で決定されるようなＣＤ１１７－である単離胎盤細胞である。別の実施形態では、本明細書に記載の方法及び組成物に有用な単離胎盤細胞は、ＣＤ１０＋、ＣＤ２９－、ＣＤ５４＋、ＣＤ２００＋、ＨＬＡ－Ｇ－、ＭＨＣクラスＩ＋、及びβ－２ミクログロブリン＋である単離胎盤細胞、例えば、胎盤幹細胞または胎盤多分化能細胞である。別の実施形態では、本明細書に記載の方法及び組成物に有用な単離胎盤細胞は、少なくとも１つの細胞マーカーの発現が間葉系幹細胞（例えば、骨髄由来間葉系幹細胞）場合よりも少なくとも２倍高い、胎盤細胞である。別の具体的な実施形態では、該単離胎盤細胞は、由来が非母体である。別の具体的な実施形態では、該細胞集団中の該細胞の少なくとも約４０％、４５％、５０％、５５％、６０％、６５％、７０％、７５％、９０％、８５％、９０％、９５％、９８％、または９９％は、由来が非母体である。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022143365A JP2022184911A (ja) | 2014-09-26 | 2022-09-09 | 胎盤幹細胞を使用する糖尿病性足部潰瘍の治療 |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056008P | 2014-09-26 | 2014-09-26 | |
| US62/056,008 | 2014-09-26 | ||
| US201562145551P | 2015-04-10 | 2015-04-10 | |
| US62/145,551 | 2015-04-10 | ||
| US201562151726P | 2015-04-23 | 2015-04-23 | |
| US62/151,726 | 2015-04-23 | ||
| US201562170757P | 2015-06-04 | 2015-06-04 | |
| US62/170,757 | 2015-06-04 | ||
| US201562220620P | 2015-09-18 | 2015-09-18 | |
| US62/220,620 | 2015-09-18 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516161A Division JP2017537057A (ja) | 2014-09-26 | 2015-09-25 | 胎盤幹細胞を使用する糖尿病性足部潰瘍の治療 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143365A Division JP2022184911A (ja) | 2014-09-26 | 2022-09-09 | 胎盤幹細胞を使用する糖尿病性足部潰瘍の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021001178A JP2021001178A (ja) | 2021-01-07 |
| JP2021001178A5 true JP2021001178A5 (ja) | 2022-03-02 |
Family
ID=55582072
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516161A Pending JP2017537057A (ja) | 2014-09-26 | 2015-09-25 | 胎盤幹細胞を使用する糖尿病性足部潰瘍の治療 |
| JP2020143608A Withdrawn JP2021001178A (ja) | 2014-09-26 | 2020-08-27 | 胎盤幹細胞を使用する糖尿病性足部潰瘍の治療 |
| JP2022143365A Pending JP2022184911A (ja) | 2014-09-26 | 2022-09-09 | 胎盤幹細胞を使用する糖尿病性足部潰瘍の治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516161A Pending JP2017537057A (ja) | 2014-09-26 | 2015-09-25 | 胎盤幹細胞を使用する糖尿病性足部潰瘍の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143365A Pending JP2022184911A (ja) | 2014-09-26 | 2022-09-09 | 胎盤幹細胞を使用する糖尿病性足部潰瘍の治療 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20170290861A1 (ja) |
| EP (1) | EP3197467A4 (ja) |
| JP (3) | JP2017537057A (ja) |
| WO (1) | WO2016049485A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113116933A (zh) * | 2021-04-26 | 2021-07-16 | 河北医科大学第四医院 | 一种防治糖尿病足的干细胞组合物及其应用 |
| CN114404590A (zh) * | 2022-01-24 | 2022-04-29 | 四川大学华西医院 | TGF-β抑制剂在制备治疗糖尿病足的药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210018526A (ko) * | 2006-10-06 | 2021-02-17 | 안트로제네시스 코포레이션 | 천연(텔로펩티드) 태반 콜라겐 조성물 |
| EP3088512B1 (en) * | 2010-04-07 | 2019-12-11 | Celularity, Inc. | Use of placental stem cells for treating heart and circulatory diseases by promoting angiogenesis |
| US20120171161A1 (en) * | 2010-12-30 | 2012-07-05 | Sascha Abramson | Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof |
-
2015
- 2015-09-25 WO PCT/US2015/052276 patent/WO2016049485A1/en active Application Filing
- 2015-09-25 EP EP15844825.8A patent/EP3197467A4/en not_active Withdrawn
- 2015-09-25 US US15/509,710 patent/US20170290861A1/en not_active Abandoned
- 2015-09-25 JP JP2017516161A patent/JP2017537057A/ja active Pending
-
2020
- 2020-08-27 JP JP2020143608A patent/JP2021001178A/ja not_active Withdrawn
-
2022
- 2022-09-09 JP JP2022143365A patent/JP2022184911A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021001178A5 (ja) | ||
| JP2002517227A5 (ja) | 造血幹細胞を試験管内で維持する方法と組成物 | |
| MX2020004578A (es) | Composiciones de casz y metodos de uso. | |
| ES2599331T3 (es) | Tratamiento de enfermedades y trastornos relacionados con el sistema inmunitario usando células adherentes derivadas del amnios | |
| CY1121857T1 (el) | Ενωσεις οι οποιες επεκτεινουν αιμοποιητικα βλαστοκυτταρα | |
| SA517390590B1 (ar) | Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة | |
| BR112018076306A2 (pt) | composições e métodos para a supressão de células cd117+ | |
| CO2021006362A2 (es) | Construcciones de ácido nucleico y métodos de uso | |
| JP2008546397A5 (ja) | ||
| JP2019533452A5 (ja) | ||
| PH12019500187A1 (en) | A method of isolating mesenchymal stem cells from umbilical cord amniotic membrane using a cell culture medium | |
| AU2021203074A1 (en) | Placental-derived stem cells to restore the regenerative engine, correct proteomic defects and extend lifespan | |
| WO2018097540A3 (ko) | 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물 | |
| CR11006A (es) | Obtencion, aislamiento y crioconservacion de celulas endometriales/ mestruales | |
| NZ712789A (en) | Placental stem cell populations | |
| NO20062709L (no) | Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller | |
| MX2021014306A (es) | Composiciones y métodos para la modificación de cd33. | |
| CO2020015707A2 (es) | Casetes de expresión de α-glucosidasa de ácido optimizado con codón y métodos de uso del mismo | |
| MX2020010724A (es) | Metodos para preparar composiciones proteicas estables. | |
| WO2006039396A3 (en) | Non-embedded tissue microarray technology for protein and nucleic acid analyses | |
| AU2019356414A8 (en) | Binding proteins specific for HA-1H and uses thereof | |
| WO2021087368A3 (en) | Anti-cd45 antibodies and conjugates thereof | |
| WO2006090286A3 (en) | Method of obtaining a population of human haemopoietic stem cells | |
| AP2368A (en) | Novel expression vectors and uses thereof. | |
| EP4234686A3 (en) | Transduction and expansion of cells |